Status: Recruiting
Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Participants needed: 60
Trial details
Age: 55-85Biological sex: AllType: InterventionalSponsor: CKD Bio CorporationUpdated: Mar 30, 2026Locations: 2
Eligibility criteria
Male and female adults aged ≥55 and ≤85 years at the time of written consent [+3]
Subjects with clinically significant diseases other than Alzheimer's disease tha... [+17]